Introduction
============

Autoimmune inflammatory diseases affect approximately 7.6--9.4% of the world population, especially among the young and middle-aged women ([@B33]; [@B13]). Frequently accompanied by severe and chronic morbidity, autoimmune diseases are also leading causes of death all around world. The patients with autoimmune inflammatory diseases need intensive medical intervention, which imposes the huge burden on public health service and economy ([@B13]). Excessive and prolonged activation of immune cells, such as T and B lymphocytes, and overexpression of the master pro-inflammatory cytokine tumor necrosis factor alpha (TNF), together with other mediators such as interlukin-6 (IL-6), interlukin-1 (IL-1), and interferon gamma (IFN-γ), play a central role in the pathogenesis of autoimmune inflammatory responses in rheumatoid arthritis (RA), inflammatory bowel disease (IBD), Crohn's disease (CD), and ankylosing spondylitis (AS) ([@B94]; [@B127]; [@B43]).

Non-steroidal anti-inflammatory drugs (NSAIDs), glucocorticoids, disease-modifying antirheumatic drugs (DMARDs) are traditionally used in the treatment of autoimmune inflammatory diseases. NSAIDs and glucocorticoids are effective in the alleviation of pain and inhibition of inflammation, while DMARDs have the capacity of reducing tissue and organ damage caused by inflammatory responses ([@B129]). More recently, treatment for RA and other autoimmune diseases has been revolutionized with the discovery that TNF is critically important in the development of the diseases ([@B92]). Anti-TNF biologics (such as infliximab, adalimumab, etanercept, golimumab, and certolizumab pepol) have markedly improved the outcome of the management of autoimmune inflammatory diseases ([@B90]). However, a considerable proportion of patients do not respond to anti-TNF treatment ([@B112]). Moreover, anti-TNF biologics are expensive, and are associated with some adverse effects. Recent studies indicate that specifically targeting of one of TNF receptors may represent a more effective and safer treatment for autoimmune disorders. In this review, the history of development of anti-inflammatory drugs, from small molecules to anti-TNF antibodies, will be discussed.

Non-Steroidal Anti-Inflammatory Drugs (NSAIDs)
==============================================

The Historical Development of NSAIDs
------------------------------------

Plant parts such as leaves of myrtle (Myrtus), bark of willow tree (Salix), bark of poplar (Populus), and meadow sweet (Spirea) were used in fork medicine for centuries in the treatment of fever, pain, and inflammatory responses ([@B67]). These medicinal plants represented a primitive form of anti-inflammatory drugs. In the mid-19th century, salicylates were identified as active components of *Willow* spp. responsible for the anti-inflammatory activity, which laid the foundation for the mass synthesis of acetylsalicylic acid in 1899 ([@B132]; [@B136]). The progress in chemistry in the 19th--20th centuries promoted the fast development of NSAIDs. Initially, most of NSAIDs were the organic acid, but the non-acidic compounds were also discovered later. With outstanding safety profiles at dose ranges, ibuprofen was the first NSAIDs approved in the United Kingdom ([@B14]). After that, pharmaceutical companies began to develop NSAIDs with a series of chemical and biological properties ([@B107]). Overall, Post-World War II, the development of NSAIDs had experienced two periods: one was the pre-prostaglandin period (∼1970s) and another one was from 1970s to the end of the last century in which drugs were screened and evaluated partially based on their effect on the production of prostaglandin ([@B107]).

The Discovery of NSAIDs
-----------------------

Salicylic acid was synthesized by the Gerland in 1853 for the first time, and acetylsalicylic acid was synthesized by Charles Gerhardt in 1853 ([@B59]; [@B60]). Until 1876, salicylic acid was firstly used in clinic for the treatment of rheumatic disorders by two German physicians, Drs Streicher and Reiss ([@B67]). Acetylsalicylic acid was re-discovered by Hoffman in 1897 ([@B70]), and it became available worldwide in the treatment of rheumatic disorders and pain since then ([@B67]). Acetyl-salicylate was first used as Aspirin in 1899 ([@B132]). The development of aspirin, a prototype of NSAIDs, was a landmark ([@B132]), which was followed by the development of phenylbutazone (1946) and indomethacin (1963) ([@B120]). The term of 'non-steroidal anti-inflammatory drug' was used for the first time when phenylbutazone was introduced 3 years later as an anti-inflammatory agent. Thus, aspirin, phenylbutazone, and indomethacin were founding members of NSAID family.

The Categories of NSAIDs
------------------------

Non-steroidal anti-inflammatory drugs have the analgesic, antipyretic, and anti-inflammatory effect, frequently used for the treatment of conditions like arthritis and headaches ([@B107]). NSAIDs relieve pain through blocking cyclooxygenase (COX) enzymes ([@B124]). COX promotes the production of prostaglandins, a mediator which causes inflammation and pain ([@B124]). Although NSAIDs have different chemical structures, all of them have the similar therapeutic effect, e.g., inhibition of autoimmune inflammatory responses ([@B107]). In general, NSAIDs can be divided into two broad categories: traditional non-selective NSAIDs and selective cyclooxygenase-2 (COX-2) inhibitors ([@B2]).

### Traditional Non-selective NSAIDs

Based on the chemical structure, the traditional non-selective NSAIDs can be classified into different sub-types ([@B2]): (1) salicylic acid derivatives: acetylsalicylic acid (aspirin), diflunisal and sulfasalazine; (2) para-aminophenol derivatives: acetaminophen; (3) fenamates: mefenamic acid, meclofenamate, flufenamic acid; (4) propionic acid derivatives: ibuprofen, naproxen, fenoprofen, ketoprofen, flurbiprofen, oxaprozin; and (5) enolic acid (oxicam) derivatives: piroxicam, tenoxicam. Most of these drugs were discovered in the pre-prostaglandins period and were developed in the 1960s. Their antipyretic, analgesic, and anti-inflammatory properties were discovered by animal studies, based on some biochemical experimental systems ([@B107]).

### Selective COX-2 Inhibitors

The anti-inflammatory effect of NSAIDs is mainly based on the inhibition of activity of cyclooxygenase (COX) enzymes ([@B124]). COX enzymes have two forms, e.g., COX-1 and COX-2. The COX-1 is constitutively expressed by the most of tissues and is responsible for the formation of prostaglandins and thromboxane A2, while the expression of COX-2 needs to be induced by inflammatory mediators ([@B2]). COX-1 plays an important role in some important physiological processes ([@B35]). Therefore, complete inhibition of both COX-1 and COX-2 inevitably results in severe side effects ([@B30]).

Inhibition of COX-1 by traditional non-selective NSAIDs causes various gastrointestinal toxicities. In order to reduce this harmful side effect, the selective COX-2 inhibitors were developed ([@B65]). The selective COX-2 inhibitors can be further divided into two categories: selective COX-2 inhibitors and highly selective COX-2 inhibitors. The selective COX-2 inhibitors include meloxicam, salicylate, and nimesulide. These drugs more selectively inhibit COX-2, as compared to their action on COX-1. The highly selective COX-2 inhibitors characterized by replacing *cis*-stilbene with one of the pendant phenyl rings by different substitutes, termed as diarylheterocycles ([@B79]), including celecoxib, rofecoxib, valdecoxib, lumiracoxib, parecoxib, and etoricoxib ([@B2]). These coxibs have the same structure of diarylheterocycles which is decisively important for their highly potent inhibitory effect on COX-2 ([@B107]).

The Side Effects of NSAIDs
--------------------------

The traditional non-selective NSAIDs are able to inhibit both COX-1 and COX-2. These drugs also inhibit platelet aggregation and cause significant gastrointestinal disorders such as bleeding, ulcers, and perforation ([@B56]). They also induce renal toxicity ([@B95]; [@B56]). In contrast, the gastrointestinal adverse effect of selective COX-2 inhibitors is markedly reduced ([@B37]). However, just like traditional non-selective NSAIDs, selective COX-2 inhibitor still have adverse effects on the cardiovascular system, including congestive heart failure, acute myocardial fraction, and even sudden death ([@B109]; [@B69]).

Glucocorticoids
===============

The glucocorticoids were discovered by Hench and Kendal in 1940s ([@B68]), through an observation that cortisone had a significant beneficial effect for patients with severe RA ([@B62]; [@B50]). The synthetic development and commercial efforts on glucocorticoids (or corticosteroids) were made in 1950--1980s, and consequently, a number of drugs were yielded ([@B97]). Since then, the synthetic glucocorticoids are extensively used in the treatment of RA, asthma and other inflammatory diseases ([@B110]). These drugs include prednisone/prednisolone, methylprednisolone, and the fluorinated glucocorticoids such as dexamethasone and betamethasone, which are more frequently used ([@B15]). Prednisone is an inactive pro-drug and its active metabolite is prednisolone ([@B55]). Usually, the prednisolone is administered once a day, while the duration of action of other glucocorticoids is longer when administered into patients with rheumatic diseases ([@B83]). The binding of glucocorticoids to its specific receptor results in the inhibition of cellular signaling pathway such as AP-1 and NF-κB, and consequently regulate the expression of cytokines and chemokines ([@B6]). We for the first time found that immunosuppressive CD4^+^Foxp3^+^ regulatory T cells (Tregs) were relatively more resistant to glucocorticoid-induced cell death ([@B21]). Furthermore, glucocorticoid selectively inhibited the proliferation of effector T cells (Teff) while promoting Treg proliferation induced by IL-2 ([@B25]). This property of glucocorticoid was harnessed to induce immune tolerance which may represent a novel approach in the treatment of autoimmune diseases ([@B74]).

Although the glucocorticoids are highly effective in the treatment of chronic diseases, they also induce severe side effects, including gastrointestinal ulcers and bleeding, infection, immunosuppression, and bone damage ([@B45]). Currently, low-doses of glucocorticoids are usually used in the treatment of autoimmune inflammatory diseases, while the adverse effects remain a major concern for prolonged usage ([@B36]; [@B107]).

Conventional Disease-Modifying Anti-Rheumatic Drugs (cDMARDs)
=============================================================

To relieve pain is a major goal in the management of RA and other arthritis. NSAIDs are able to alleviate pain and improve joint function through inhibition of inflammatory responses ([@B107]). However, NSAIDs alone do not reverse the pathological course of the autoimmune diseases ([@B129]). Glucocorticoids can partially reduce pain symptom and suppress inflammation in the short-term ([@B83]). Therefore, drugs that are capable of sustainably reducing inflammation with manageable side effects are highly desirable for the treatment of RA and other autoimmune diseases ([@B83]). For this purpose, several drugs with different chemical structures, known as "disease-modifying anti-rheumatic drugs" (DMARDs), were developed.

Methotrexate
------------

Methotrexate is an analog and antagonist of folic acid, which was synthesized firstly in 1947 ([@B128]). Methotrexate was firstly reported to be effective in the treatment of RA in 1962 ([@B77]), and after that it was also widely used as an anti-inflammatory drug for the management of other autoimmune diseases, including psoriasis, CD, and UC ([@B96]; [@B143]). Methotrexate has been used as the first-line DMARDs since it was developed, due to its long-term effectiveness, satisfying responsive rate, acceptable toxicity profile, and low cost ([@B138]; [@B48]). Fundamental mechanisms underlying the therapeutic effect of methotrexate have been elucidated. For example, methotrexate was found to competitively inhibit the activity of folate-dependent enzymes, and synthesis of purine and pyrimidine which are required for DNA and RNA synthesis, and consequently suppress lymphocyte proliferation and production of pro-inflammatory cytokines ([@B90]). Nevertheless, the methotrexate monotherapy is no longer considered as the gold standard for RA treatment, for the reason that DMARDs combination therapy is more effective ([@B82]).

Leflunomide
-----------

Leflunomide was approved for the treatment of RA in the 1998 ([@B57]). Leflunomide is an isoxazole derivative that is capable of blocking the rate-limiting enzyme dihydroorotate dehydrogenase, thereby selectively inhibits the synthesis of *de novo* pyrimidine ribonucleotides such as rUMP ([@B54]). Leflunomide is a pro-drug that is metabolized into teriflunomide *in vivo* ([@B83]). Teriflunomide is a potent inhibitor of NF-κB activation, and consequently suppresses the production of pro-inflammatory cytokines. Leflunomide also reduces the production of metalloproteinases in synovial tissue and prevents joint destruction ([@B83]). The results of meta-analyses strongly suggest that leflunomide is a DMARDs and effective in the treatment of RA ([@B103]). As shown by several studies, the therapeutic effect of leflunomide is comparable to that of methotrexate ([@B123]). Leflunomide can improve all clinical outcomes and delay radiographic progression at 6 and 12 months of RA patients ([@B116]). Therefore, leflunomide should be considered as first-line therapy if contraindications to methotrexate are present. Furthermore, leflunomide is very useful in the combination therapy ([@B73]).

Other DMARDs
------------

Except for methotrexate and leflunomide, other DMARDs, include gold compounds, sulfasalazine, azathioprine, cyclophosphamide, antimalarials, [D]{.smallcaps}-penicillamine, cyclosporine, are all effective in the treatment of autoimmune inflammatory diseases such as RA ([@B57]). The DMARDs commonly used for the treatment of RA include hydroxychloroquine, sulfasalazine, methotrexate and leflunomide, while [D]{.smallcaps}-penicillamine, azathioprine, gold compounds, and cyclosporine are used less frequently ([@B80]).

Parenteral organic gold compounds have been used for RA treatment since 1920s ([@B125]), and their effect is comparable with other DMARDs ([@B90]). Nonetheless, the toxicity of gold compounds, especially the adverse effect on skin and mucosa, is a major concern which limits their clinical application ([@B7]).

Sulfasalazine was initially investigated for the treatment of IBD, including UC and CD ([@B12]). This drug was firstly reanimated in Europe where it has been used in early RA patients. The exact mechanism of sulfasalazine is still unclear, although it inhibits the production of pro-inflammatory cytokines, including TNF and IL-6 ([@B139]). The main side effect of sulfasalazine is gastrointestinal upset or rash ([@B126]).

Antimalarial drugs hydroxychloroquine and chloroquine have the capacity to inhibit the clinical progress of several autoimmune diseases, including RA and systemic lupus erythematosus (SLE) ([@B130]). Although the exact molecular mechanism of its immunosuppressive effect remains to be fully understood, both drugs can inhibit the activation of T cells, B cells ([@B130]) and the production of pro-inflammatory cytokines such as TNF, IL-6, and IL-1β ([@B72]). Both drugs almost have the same side effects, such as rare irreversible retinopathy and a more rarely form of myopathy ([@B34]).

Combination Therapy with cDMARDs
--------------------------------

Among cDMARDs drug class, the methotrexate is still an 'anchor drug' for RA therapy, and the first choice for the most of DMARD-naïve patients ([@B48]). However, a considerable proportion of patients do not respond to methotrexate. Either anti-TNF biologics (which will be discussed later) or a combination therapy of cDMARDs should be considered for those patients ([@B134]). Methotrexate has been used in combination with other drugs, including sulfasalazine, sulfasalazine and hydroxychloroquine, cyclosporine and biologic agents such as etanercept and infliximab ([@B82]; [@B128]). For example, the concomitant treatment of methotrexate and leflunomide results in a synergistic effect in the treatment of patients with RA ([@B10]; [@B82]). The triple combination of methotrexate, sulfasalazine and hydroxychloroquine represent an effective therapy regimen since 1996 ([@B90]), which is more effective and safer than the monotherapy with methotrexate, or methotrexate combination of sulfasalazine, or hydroxychloroquine ([@B99], [@B100]). It has been reported that the combination of methotrexate and cyclosporine, or leflunomide and cyclosporine, are more effective than each drug alone ([@B75]). However, the toxicity of cyclosporine, including reversible and irreversible renal disease, hypertension and heurism, remains an important issue in the combination therapy ([@B57]). Therefore, the ideal cDMARDs combination therapy should be one that is synergistic in their efficacy while lacking additive effects of toxicity.

Anti-Tnf Biologics
==================

In 1975, Lloyd and colleagues discovered an endotoxin-inducible serum factor named TNF had the capacity to cause necrosis of tumors ([@B17]). It is one of subsequent studies of "Coley's toxin," a therapeutic regimen using killed bacteria to induce tumor regression in cancer patients, invented by Dr. William Coley in 1891 ([@B32]). Although initially identified as anti-tumor molecule, TNF is now considered as a pleiotropic cytokine which plays a major role in immune or inflammatory responses ([@B104]; [@B42]).

Feldman's group showed that a number of pro-inflammatory cytokines such as IL-1, TNF, IL-6, GM-CSF, and IFN-γ were expressed at a high levels in synovium samples from active RA patients ([@B49]). Intriguingly, anti-TNF antibody inhibited the expression of other pro-inflammatory cytokines (IL-1, IL-6, and GM-CSF) in the synovial culture ([@B49]). Furthermore, anti-TNF antibodies such as infliximab and adalimumab suppressed antigen-induced IFN-γ production in blood ([@B140]). These results provide the evidence that TNF plays a predominant role in the pathogenesis of autoimmune inflammatory diseases. IFN-γ is also an important mediator in the inflammatory responses, such as Schwartzman reactions ([@B8]) and collagen-induced arthritis ([@B87]). It was also reported that IFN-γ promoted the production of TNF induced by LPS stimulation ([@B8]). However, unlike the effect of anti-TNF biologics, treatment with antibody against IFN-γ did not markedly ameliorate the arthritic symptoms in RA patients ([@B122]; [@B115]).

TNF is now generally considered as a master pro-inflammatory cytokine that plays a critical role in the pathogenesis of autoimmune inflammatory diseases ([@B94]). Consequently, anti-TNF biologics, which are designed to block the biological function of TNF, have been developed for the therapy of autoimmune inflammatory diseases ([@B90]). In the past two decades, five TNF-targeting drugs have been approved for clinical use, including infliximab, etanercept, adalimumab, golimumab, and certolizumab pegol, for the treatment of the autoimmune inflammatory diseases including RA, CD and AS ([@B92]).

Infliximab
----------

Infliximab is a recombinant chimeric antibody that is generated by mouse myeloma cells. The structure of infliximab contains a constant sequence of human IgG1 and variable regions of murine, which is specific for all forms of TNF in human and chimpanzees, and effectively blocks the binding of TNF to its soluble and membrane receptors ([@B92]). The maximum serum concentration of infliximab can be reached within 1 h by intravenous administration ([@B4]), and the half-life is approximately 8--10 days ([@B18]). After that, infliximab can be maintained by dosing every 8 weeks. Infliximab is capable of mediating both complement-dependent and antibody-dependent cytotoxicity on a cell line overexpressing TNF ([@B131]). Infliximab is initially approved for the treatment of Crohn's disease by the US Food and Drug Administration (FDA) and later also for RA. It was further approved for the treatment of AS, PsA, UC, CD, and chronic plaque psoriasis ([@B4]).

Etanercept
----------

Etanercept comprises soluble TNF receptor 2 and Fc portion of IgG1, which is a human recombinant protein ([@B76]). After subcutaneous administration, etanercept has a half-life of 3--3.5 days ([@B18]). Etanercept binds to and inactivates soluble form and membrane form of TNF and lymphotoxin, by blocking their interaction with the receptors ([@B131]). Similar as infliximab, etanercept alleviate the signs and symptoms of arthritis and inhibits progress of RA in patients ([@B93]). Furthermore, it is more effective when combined with methotrexate ([@B44]). Etanercept is also approved by FDA for the treatment of juvenile rheumatoid arthritis and PsA, RA, PP, and AS ([@B76]).

Adalimumab
----------

Adalimumab is a fully humanized IgG1 monoclonal antibody, which can specific block human TNF binding to its receptors ([@B4]). Adalimumab needs a less frequent subcutaneous injection because of its relative longer half-life which is about 2 weeks ([@B125]). Furthermore, adalimumab shows the lower immunogenicity than infliximab ([@B108]).

Adalimumab is effective in alleviating the signs and symptoms of moderate to severe RA patients ([@B133]). Adalimumab is also effective in the treatment of patients with CD, with good tolerance and minimal immunogenicity, thus can be used in patients with allergic reactions to infliximab ([@B113]). Adalimumab has been approved by FDA for the treatment of autoimmune diseases including RA, PsA, AS, and CD ([@B84]).

Golimumab
---------

Golimumab is also a fully humanized IgG1 monoclonal antibody, which has a high affinity and specificity for human TNF ([@B117]). As shown by the preclinical data, golimumab has higher affinity and is more effective in the neutralization of soluble and trans-membrane forms of TNF, as compared with infliximab and adalimumab, thus it can potently neutralize TNF biological activity ([@B118]). The half-life of golimumab is about 7--20 days ([@B146]). Golimumab was approved by the FDA in 2009 for the treatment of moderate-to-severe RA when administrated in combination with methotrexate ([@B88]). It was also approved for UC treatment by FDA and European Medicines Agency (EMA) in 2013 ([@B86]).

Certolizumab Pegol
------------------

Certolizumab pegol (CDP870) is a humanized monoclonal antibody with the structure of polyethylene glycolated Fab fragment, which is a novel TNF inhibitor with a distinct mechanism of action compared with other TNF inhibitors ([@B105]). The unique structure might be an explanation for certolizumab pegol with higher efficiency in comparison with other TNF inhibitors ([@B39]). PEGylation of certolizumab pegol improves its half-life to 2 weeks which may contribute to its high concentration in the inflamed tissues ([@B78]).

Certolizumab pegol monotherapy could effectively control the symptoms of patients with RA ([@B31]). It is also effective the treatment of patients with moderate to severe CD ([@B114]). Certolizumab pegol has been approved for the treatment of CD and PsA by FDA ([@B38]).

Biosimilars
-----------

Biosimilar has been defined as a biological medicinal product that has the similar quality, safety, and efficacy with the already approved biological medicine ([@B51]). Anti-TNF biosimilars that are extensively developed in recent years will help reduce the cost of anti-TNF treatment. To date, a number of anti-TNF biosimilar products (summarized in **Table [1](#T1){ref-type="table"}**) have been marketed ([@B40]). CT-13 is the first biosimilar monoclonal antibody against TNF. Comparing with the original TNF inhibitor infliximab, CT-13 is equally effective and safe ([@B144]). It is approved in European for the treatment of RA, AS, PsA, PS, CD, and UC ([@B41]).

###### 

Anti-TNF biosimilars in the development for the treatment of autoimmune inflammatory diseases.

  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Anti-TNF biologics   Biosimilar    Indicates           Current development stage in May 2017                        Sponsor
  -------------------- ------------- ------------------- ------------------------------------------------------------ ---------------------------------------------------
  Infliximab           ABP 710       RA                  Phase III in RA                                              Amgen

                       BCD-055       RA, Psoriasis, AS   Phase III in RA, Psoriasis\                                  Biocad
                                                         Phase I completed in AS                                      

                       BOWO15        RA                  Phase III in RA                                              Epirus Biopharmaceuticals (Switzerland) GmbH

                       CT-P13        RA,CD,AS            Phase III completed in CD, RA\                               Celltrion
                                                         Phase III completed in AS                                    

                       NI-071        RA                  Phase III completed in RA                                    Nichi-Iko Pharmaceutical Co., Ltd.

                       PF-06438179   RA                  Phase III in RA                                              Pfizer

                       SB2           RA                  Phase III completed in RA                                    Ohio State University Comprehensive Cancer Center

  Etanercept           CHS-0214      RA,PP               Phase III completed in RA and PP                             Coherus Biosciences, Inc.

                       ENIA11        RA                  Phase III in RA                                              TSH Biopharm Corporation Limited

                       GP2015        RA,PP               Phase III completed in RA, Chronic Stable Plaque Psoriasis   Sandoz

                       HD203         RA                  Phase III completed in RA                                    Hanwha Chemical

                       LBEC0101      RA                  Phase III in RA                                              LG Life Sciences

                       SB4           RA                  Phase III completed in RA                                    Samsung Bioepis Co., Ltd.

  Adalimumab           ABP 501       RA, Psoriasis       Phase III completed in RA and Psoriasis                      Amgen

                       BCD-057       Psoriasis           Phase III in Psoriasis                                       Biocad

                       BI 695501     RA                  Phase III completed in RA                                    Boehringer Ingelheim

                       CHS-1420      PP                  Phase III completed in PP                                    Coherus Biosciences, Inc.

                       GP2017        RA, Psoriasis       Phase III completed in Plaque Type Psoriasis\                Sandoz
                                                         Phase III in RA                                              

                       LBAL          RA                  Phase III in RA                                              LG Life Sciences

                       M923          RA                  Phase III completed in RA                                    Momenta Pharmaceuticals, Inc.

                       PF-06410293   RA                  Phase III in RA                                              Pfizer

                       MSB11022      RA, PsA, PP         Phase III in RA, PsA, PP                                     EMD Serono Research & Development Institute, Inc.

                       SB5           RA                  Phase III completed in RA                                    Samsung Bioepis Co., Ltd.

  Golimumab            BOW100        AS,PsA,RA,UC        Preclinical                                                  Bioceros

                       ONS-3035      RA, UC              Preclinical                                                  Oncobiologics

  Certolizumab pegol   PF688         RA, CD              Preclinical                                                  Pfenex

                       Xcimzane      RA, PsA, UC, AS     Preclinical                                                  Xbrane
  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------

The Side Effects of Anti-TNF Biologics
--------------------------------------

Although anti-TNF biologics are generally effective in the treatment of patients with different autoimmune inflammatory diseases ([@B142]), not all patients respond equally well to the treatment. Up to 40% of patients have no response to anti-TNF treatment ([@B112]). Furthermore, several types of adverse effects have been associated with anti-TNF biologics.

It was reported recently that PBMCs isolated from patients responding to the treatment of adalimumab and etanercept can produce higher levels of TNF and soluble TNFR2 (sTNFR2) than those from patients responding to infliximab, and PBMCs isolated from patients who do not respond to infliximab produce higher levels of TNF and sTNFR2 than those from patients responding to infliximab ([@B61]). Therefore, anti-TNF biologics may have major and different effects on TNF expression and soluble TNFR2 levels in patients. It was reported that the TNF gene polymorphism (TNF-alpha 308G \> A) is association with patients who do not respond to anti-TNF therapy ([@B141]). Furthermore, the polymorphism of tumor necrosis factor receptor superfamily member 1B, a gene encoding TNFR2 protein, is able to predict responses of patients with autoimmune diseases to anti-TNF therapy ([@B19]). Thus, aberrant expression of TNF and TNFR2, and their responses to TNF blockade, is responsible at least partially for the outcome of anti-TNF therapy.

TNF plays a crucial role in host defense to invading pathogens ([@B106]). Anti-TNF biologics can inhibit IFN-γ expression in the blood ([@B140]). In addition, TNF is a good inducer of nitric oxide (NO) in macrophage, and TNF also synergizes with IFN-γ in inducing inducible nitric oxide synthase (iNOS) ([@B137]), while iNOS is able to synthesize antimicrobial nitric oxide ([@B46]). This can explain why infections, such as tuberculosis and pneumonia, are common adverse event of patients treated with anti-TNF biologics ([@B3]).

There is also some evidence that anti-TNF treatment is associated with increased risk of malignancy ([@B11]). However, this is not supported by the more recent studies ([@B91]; [@B119]). In fact, the underlying inflammatory condition is likely to promote the development of cancer, while anti-inflammatory treatment has the beneficial effect in inhibition of malignancy ([@B85]). For example, patient with RA and CD has a higher risk of lymphoma compared with the general population ([@B3]). Therefore, patients with malignancy after treatment with anti-TNF biologics should be more carefully studied.

Anti-TNF treatment has been tried in patients with congestive cardiac failure, since the high levels of circulating TNF was found in such patients. However, infliximab, adalimumab, and etanercept have deleterious, rather than beneficial, effects on congestive cardiac failure patients ([@B5]). Anti-TNF biologics have been reported to have side effects on the neurological system. For example, anti-TNF treatment exacerbated diseases in almost all multiple sclerosis (MS) ([@B111]). Paradoxically, some new autoimmune diseases can be *de novo* induced by anti-TNF therapy. For example, psoriasis can be induced in IBD patients treated with anti-TNF biologics ([@B66]). Therefore, more effective and safer TNF-targeting treatment needs to be developed. Thorough understanding of the fundamental biology of TNF and it receptors is a prerequisite to reach this goal.

Anti-TNFR Therapeutics: Next Generation of TNF-Targeting Drug?
==============================================================

Tumor necrosis factor-alpha is a pleiotropic cytokine that is involved in the initiation and orchestration of inflammation and immunity ([@B1]). Two receptors of TNF, namely TNFR1 (P55) and TNFR2 (P75), mediate different signaling pathways and induce diverse biological effects of TNF ([@B135]). TNFR1 is expressed by almost all cell types except erythrocyte, whereas TNFR2 is more strictly expressed by immune cells. The capacity of TNF to induce cell death is mediated by TNFR1. Conversely, TNFR2 signaling triggers cell survival pathways and promotes cell proliferation ([@B47]). Initially, TNF is expressed on the cell surface as a transmembrane protein. It is then cleaved by a metalloprotease, called TNF-alpha converting enzyme (TACE) ([@B9]). This process liberates a trimeric soluble protein, namely soluble TNF (sTNF). Both membrane-bound TNF and soluble TNF can bind to TNFR1 and TNFR2, but membrane-bound TNF preferentially binds with TNFR2 ([@B64]).

There is now compelling evidence that TNFR2 is constitutively expressed by immunosuppressive CD4^+^Foxp3^+^ regulatory T cells (Tregs) and TNF-TNFR2 interaction preferentially activates and expands naturally occurring Tregs ([@B20], [@B27], [@B26], [@B29]; [@B98]). The immunosuppressive property of TNFR2 has been shown by many studies. For example, TNFR2 agonist is able to promote the expansion of Tregs more potently than TNF itself, and consequently inhibits autoimmune responses ([@B101]). Selective blockade of TNFR1 also results in the proliferative expansion and activation Tregs ([@B89]), and inhibits clinical symptoms in CIA model ([@B121]). It was shown recently that therapeutic anti-TNF antibody Infliximab binds to and promotes the expression of membrane bound TNF on monocytes from RA patients, and consequently enhances Treg activity through TNF-TNFR2 interaction ([@B24]; [@B98]). These evidences favor the idea that biologic drugs which can selectively inhibit TNFR1, or selectively activate TNFR2, may be more effective and safer than those globally inhibit TNF. The expression of TNFR2 on cells and tissues is more limited than TNFR1. Thus, therapeutically targeting TNFR2 may have fewer side effects than targeting TNFR1. Expression of TNFR2 on CD4^+^Foxp3^-^ effector T cells (Teffs) can be induced and upregulated by TCR stimulation, and TNFR2 expression on Teff cells has a functional consequence ([@B23]; [@B63]; [@B28]; [@B24]; [@B22]; [@B145]). Thus, the effect of TNFR2 on Teff function should be considered in the development of TNFR2-targeting therapeutics.

Other Biological Drugs for Autoimmune Inflammatory Diseases
===========================================================

In addition to anti-TNF agents, the biologics targeting other proinflammatory cytokines or immune competent molecules have also been extensively studied and actively developed. For example, abatacept, a fully humanized fusion protein of extracellular domain of CTLA-4 and Fc fraction of IgG1, has been approved for the RA patients with inadequate response to anti-TNF therapy ([@B58]). The major immunological mechanism of abatacept is selective inhibition of co-stimulation pathway (CD80 and CD86) and activation of T cells. Tocilizumab, a humanized anti-IL-6 receptor monoclonal antibody was approved for RA patients intolerant to DMARDs and/or anti-TNF biologics ([@B102]). This therapeutic mAb blocks the transmembrane signaling of IL-6 through binding with soluble and membrane forms of IL-6 receptor. Biological drugs targeting IL-1 (anakinra), Th1 immune responses (IL-12/IL-23, ustekinumab), Th17 immune responses (IL-17, secukinumab) and CD20 (rituximab) have also been approved for the treatment of autoimmune diseases, as summarized in the **Table [2](#T2){ref-type="table"}**, as a complementary and alternative biological treatment of anti-TNF therapy.

###### 

Alternative biologic in autoimmune inflammatory diseases.

  Drug                    Target                                                              Type of molecules                                          Indications                                      Reference
  ----------------------- ------------------------------------------------------------------- ---------------------------------------------------------- ------------------------------------------------ -----------
  Abatacept (Orencia)     CD80 (B7-1) and CD86 (B7-2) and blocks activation of T-cell Ab4Ig   The extracellular domain of CTLA4 and Fc domain of IgG1    RA, JIA, SLE                                     [@B58]
  Tocilizumab (Actemra)   IL-6                                                                A humanized anti-human IL-6 receptor monoclonal antibody   RA after treatment failure with TNF inhibitors   [@B102]
  Anakinra (Kineret)      IL-1                                                                A recombinant human IL-1 receptor antagonist               RA                                               [@B53]
  Ustekinumab             IL-12 and IL-23                                                     Human IgG1k mAb                                            Psoriasis                                        [@B81]
  Rituximab               CD20                                                                A chimeric murine/human monoclonal IgG1k antibody          RA, SLE                                          [@B52]
  Secukinumab             IL-17                                                               A human IgG1κ monoclonal antibody                          PP                                               [@B16]

CTLA, cytotoxic T lymphocyte-associated; JIA, juvenile idiopathic arthritis; SLE, systemic lupus erythematosus.

Conclusion
==========

Although TNF plays a central role in acute and chronic inflammation, the anti-inflammatory agents were developed before the identification of TNF. After the World War II, agents from small molecules to anti-TNF antibodies have been developed, including NSAIDs, glucocorticoids, DMSADs, and anti-TNF biologics. The traditional non-selective NSAIDs are associated with severe gastrointestinal disorders, attributable to simultaneous inhibition of COX-1 and COX-2, which prompted the development of selective NSAIDs. Glucocorticoids have potent anti-inflammatory activity, accompanied by some severe adverse effects. Methotrexate remains the first-line drug, while the efficacy can be enhanced and adverse effects can be reduced by DMARDs combination therapy. Currently, five anti-TNF biologics have been approved for patients with autoimmune disorders. With great success in treating autoimmune diseases, anti-TNF biologics also represent the most profitable drug class in the history, exceeding \$US 25 billion total sale in 2012 ([@B92]). Anti-TNF biosimilars bring the hope to reduce the medical costs and consequently improve the accessibility to this revolutionized treatment. Nevertheless, the effectiveness and safety of TNF-targeting treatment should be further improved, hopefully through the selective blockade of TNFR1 or activation of TNFR2. For those patients failed to respond appropriately to anti-TNF treatment, biologics targeting other pro-inflammatory cytokines and pathways provide an alternative therapy.

As compared to small molecule compounds, biologics have some clear advantages, such as higher safety profile or minimal toxicity, well-understood mechanisms, and more importantly, the target specificity ([@B131]; [@B90]; [@B92]). Due to these advantages, the biologics, including therapeutic monoclonal antibodies and antibody-drug conjugate (ADC), have become main stream therapeutics ([@B90]; [@B92]). This class of drug represents the fastest growing segment of global pharmaceutical marked (based on the data of global sale and FDA approval) ([@B71]; [@B92]). Therefore, it is predictable that the development of new biologics for the treatment of autoimmune diseases will be the focus in the future, which will be facilitated by the more thorough understanding of molecular basis of autoimmune diseases.
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